Related Experiment Videos
[Clinical studies of S-1108 fine granules in pediatrics]
H Morita1, Y Morisawa, F Hamada
1Department of Pediatrics, Kochi Medical School.
Insights
S-1108 fine granules demonstrated high therapeutic effectiveness in children, with an 87.5% efficacy rate for bacterial infections. This promising drug showed no adverse reactions in clinical trials, making it a safe treatment option.
Area of Science:
- Pediatric infectious diseases
- Pharmacology
- Clinical microbiology
Background:
- Bacterial infections pose a significant health concern in pediatric populations.
- Effective and safe antimicrobial agents are crucial for treating childhood infections.
Purpose of the Study:
- To evaluate the therapeutic effectiveness and safety of S-1108 fine granules in children with bacterial infections.
- To determine the efficacy and bacteriological eradication rates of S-1108.
Main Methods:
- A clinical study involving 16 children diagnosed with various bacterial infections.
- Administration of S-1108 fine granules at doses of 8.8–10.6 mg/kg body weight in divided portions.
- Treatment durations varied from 2 to 15 days, with ongoing monitoring for therapeutic response and adverse events.
Main Results:
- An overall therapeutic efficacy rate of 87.5% was observed, with 1 excellent and 13 good responses.
- A high bacteriological eradication rate of 91% was achieved.
- No adverse reactions were reported in any of the participants, although one patient exhibited eosinophilia in laboratory tests.
Conclusions:
- S-1108 fine granules exhibit promising therapeutic effectiveness and a favorable safety profile for treating bacterial infections in children.
- The drug's high efficacy and eradication rates suggest its potential as a valuable antimicrobial option in pediatric care.
Abstract:
We have evaluated S-1108 fine granules for therapeutic effectiveness in children. The results are summarized as follows. 1. A clinical study was performed with 16 children with infections, including 8 with acute tonsillitis, 3 with acute pharyngitis, 2 with scarlet fever, 1 each with acute bronchitis, pertussis and urinary tract infection. Doses ranging from 8.8 to 10.6 mg/kg body weights were given in 3 divided portions. Durations of treatment ranged from 2 to 15 days. The therapeutic responses were considered "excellent" in 1 and "good" in 13, with an efficacy rate of 87.5%, and the bacteriological eradication rate was 91%. 2. No adverse reactions were observed. In laboratory tests, eosinophilia was observed in one patient. It was concluded the S-1108 was promising drug for the treatment of bacterial infections in children.